Alpine Immune Sciences Inc banner
A

Alpine Immune Sciences Inc
F:34LA

Watchlist Manager
Alpine Immune Sciences Inc
F:34LA
Watchlist
Price: 59 EUR Market Closed
Market Cap: €4B

Alpine Immune Sciences Inc
Accounts Payable

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Alpine Immune Sciences Inc
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
A
Alpine Immune Sciences Inc
F:34LA
Accounts Payable
$4.2m
CAGR 3-Years
103%
CAGR 5-Years
43%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Accounts Payable
$34.7B
CAGR 3-Years
11%
CAGR 5-Years
11%
CAGR 10-Years
23%
Gilead Sciences Inc
NASDAQ:GILD
Accounts Payable
$715m
CAGR 3-Years
-8%
CAGR 5-Years
-3%
CAGR 10-Years
-5%
Amgen Inc
NASDAQ:AMGN
Accounts Payable
$20.9B
CAGR 3-Years
137%
CAGR 5-Years
71%
CAGR 10-Years
36%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accounts Payable
$3.9B
CAGR 3-Years
134%
CAGR 5-Years
91%
CAGR 10-Years
48%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accounts Payable
$6.8B
CAGR 3-Years
126%
CAGR 5-Years
70%
CAGR 10-Years
47%
No Stocks Found

Alpine Immune Sciences Inc
Glance View

Market Cap
4B EUR
Industry
Biotechnology

Alpine Immune Sciences Inc., a biotechnology company, stands poised at the intersection of innovation and necessity, carving its niche in the fast-paced world of immune system modulation. Founded to address the complex challenges of autoimmune inflammation and cancer, Alpine harnesses the intricate mechanisms of the immune system to develop novel therapies. The company's unique approach centers around their proprietary platform, the "Directed Evolution" technique, which enhances the body's natural defenses by evolving proteins to selectively target cells and pathways. This approach aims to balance efficacy with safety—a critical factor in immunotherapy—to not just treat but possibly transform the landscape of autoimmune and cancer treatments. In this innovative pursuit, Alpine generates revenue through a multi-pronged business model, leveraging both partnerships and proprietary product development. The company actively collaborates with big-name players in the pharmaceutical industry, securing milestone payments, and royalties that provide financial footing. Their pipeline, rich with potential candidates, further positions Alpine for future commercial success, especially as its therapies advance into later stages of clinical trials. By focusing on high-need areas and utilizing strategic collaborations, Alpine Immune Sciences is steadily building a sustainable business model while offering a beacon of hope for patients looking for more effective treatment options.

34LA Intrinsic Value
Not Available

See Also

What is Alpine Immune Sciences Inc's Accounts Payable?
Accounts Payable
4.2m USD

Based on the financial report for Mar 31, 2024, Alpine Immune Sciences Inc's Accounts Payable amounts to 4.2m USD.

What is Alpine Immune Sciences Inc's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
43%

Over the last year, the Accounts Payable growth was 145%. The average annual Accounts Payable growth rates for Alpine Immune Sciences Inc have been 103% over the past three years , 43% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett